Noema Pharma, a clinical-stage Swiss biotech startup targeting debilitating central nervous system (CNS) disorders, has raised additional funding, closing its Series B round at $147 million. The investment came from EQT Life Sciences, which recently invested in Nua Surgical. The investor joined the syndicate of previous Series B investors, including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
This follows the initial $112 million Series financing secured last year and the $60 million Series A investment raised in 2020.
The new financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025.
What does Noema Pharma do?
Founded in 2019 and led by CEO Ilise Lombardo, Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet needs. The company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorders.
Clinical trials in the pipeline
Noema is currently investigating multiple compounds in clinical trials for the following:
- Basimglurant (NOE-101), a mGluR5 negative allosteric modulator in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC).
- Gemlapodect (NOE-105), a PDE10a inhibitor in Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering).
- NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.
Ilise Lombardo, MD, CEO of Noema Pharma, stated: “This latest financing underscores the strong support and confidence from investors in Noema’s vision to treat neuroscience-based conditions. We are thrilled to welcome EQT Life Sciences into this strong syndicate of investors and have Felice join our Board. EQT’s support and expertise alongside our syndicate of investors will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”
Felice Verduyn-van Weegen, Partner at EQT and member of the Board at Noema, commented: “Noema Pharma’s innovative approach to CNS disorders aligns very well with our investment strategy and we are excited to support their late-stage clinical pipeline and transformative therapies. Having worked with Ilise Lombardo on a previous successful investment, her exceptional leadership as a repeat entrepreneur reinforces our confidence in Noema’s potential to deliver meaningful impact to patients in need.”
The post Swiss biotech Noema Pharma closes $147M funding to support Phase 2 clinical trials appeared first on Tech Funding News.